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Abstract
Background: Diminished calcium (Ca2+) transients in response to physiological agonists have been reported in
vascular smooth muscle cells (VSMCs) from diabetic animals. However, the mechanism responsible was unclear.
Methodology/Principal Findings: VSMCs from autoimmune type 1 Diabetes Resistant Bio-Breeding (DR-BB) rats
and streptozotocin-induced rats were examined for levels and distribution of inositol trisphosphate receptors (IP3R)
and the SR Ca2+ pumps (SERCA 2 and 3). Generally, a decrease in IP3R levels and dramatic increase in ryanodine
receptor (RyR) levels were noted in the aortic samples from diabetic animals. Redistribution of the specific IP3R
subtypes was dependent on the rat model. SERCA 2 was redistributed to a peri-nuclear pattern that was more
prominent in the DR-BB diabetic rat aorta than the STZ diabetic rat. The free intracellular Ca2+ in freshly dispersed
VSMCs from control and diabetic animals was monitored using ratiometric Ca2+ sensitive fluorophores viewed by
confocal microscopy. In control VSMCs, basal fluorescence levels were significantly higher in the nucleus relative to
the cytoplasm, while in diabetic VSMCs they were essentially the same. Vasopressin induced a predictable increase
in free intracellular Ca2+ in the VSMCs from control rats with a prolonged and significantly blunted response in the
diabetic VSMCs. A slow rise in free intracellular Ca2+ in response to thapsigargin, a specific blocker of SERCA was
seen in the control VSMCs but was significantly delayed and prolonged in cells from diabetic rats. To determine
whether the changes were due to the direct effects of hyperglycemica, experiments were repeated using cultured
rat aortic smooth muscle cells (A7r5) grown in hyperglycemic and control conditions. In general, they
demonstrated the same changes in protein levels and distribution as well as the blunted Ca2+ responses to
vasopressin and thapsigargin as noted in the cells from diabetic animals.
Conclusions/Significance: This work demonstrates that the previously-reported reduced Ca2+ signaling in VSMCs
from diabetic animals is related to decreases and/or redistribution in the IP3R Ca
2+ channels and SERCA proteins.
These changes can be duplicated in culture with high glucose levels.
Background
While improved care for people with diabetes has
reduced the overall risk of complications and mortality,
rates of mortality for people with diabetes is still two
fold higher than those without diabetes [1,2]. Cardiovas-
cular disease accounts for a significant percentage of
deaths of individuals inflicted with type 1 diabetes [3-7].
Even in young adults, cardiovascular events such as
stroke are higher in people with type 1 diabetes than in
those without diabetes [8]. As the duration of life with
diabetes increases, so increases the risk of cardiovascular
events and mortality [9]. Current management proce-
dures focusing on tight glycemic control may have only
marginal effects to halt the progression of large vessel
disease [10].
While the majority of research effort concerning dia-
betic vascular disease has been focused on changes in
the endothelial cells, alterations in the vascular smooth
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muscle cells (VSMCs) are also known to occur [11-13].
The VSMCs surrounding vessel walls, undergo increased
proliferation, adhesion, and migration in conditions of
hyperglycemia [14-17]. Several proteins and genes have
been proposed as targets for hyperglycemic changes in
the VSMCs including protein kinase C (PKC). Interest-
ingly, many of them have a common upstream pathway
that includes the release of calcium (Ca2+) from intracel-
lular stores, including the sarcoplasmic reticulum (SR).
In VSMCs there are two channels that have been
identified as important in the release of intracellular Ca2
+ stores; the inositol 1,4,5-trisphosphate (IP3)-sensitive
store and the ryanodine-sensitive store [18]. In VSMCs,
IP3 release of Ca
2+ from intracellular stores is a com-
mon pathway for activation of many proteins including
PKC [19] and PLC. Changes in basal levels of intracellu-
lar Ca2+ with diabetes are inconsistent, but Ca2+ transi-
ents in response to agonists such as angiotensin II are
clearly attenuated in VSMCs from diabetic animals [20].
The blunted IP3-induced Ca
2+ responses could be due
to changes in the intracellular Ca2+ channels, the intra-
cellular Ca2+ storage site (SR), or the sarcoplasmic/
endoplasmic Ca2+ ATPase (SERCA). This study exam-
ines changes in the intracellular Ca2+ regulatory proteins
in two animal models of type 1 diabetes. The streptozo-
tocin-induced diabetic rat is a well-established rat model
using a toxin to destroy the pancreatic beta cells. The
second model utilizes the DR-BB rat, which better
mimics the autoimmune component of type 1 diabetes.
Results from these animal models were compared to a




Seven week old male Sprague Dawley rats (Harlan,
Indianapolis, IN) weighing 250-270 grams were injected
intraperitoneally with 65 mg streptozotocin (STZ,
Sigma, St. Louis, MO) per kg body weight (n = 15).
Non-diabetic control rats (n = 12) were injected with
vehicle (citrate buffer). Blood glucose levels greater than
250 mg/dL, measured by an Accu-Check Advantage
glucometer (Boehringer Mannheim Corporation, India-
napolis, IN), indicated the development of diabetes.
The blood glucose levels and body weights of all rats
were assessed weekly. The final weight and blood glu-
cose levels are shown in Table 1. Free access to food
and water was supplied. The principles of institutional
laboratory animal care were strictly followed. The rats
were killed with an intraperitoneal injection of pentobar-
bital after 8 weeks of diabetes.
DR-BB Rat Model
Diabetes was induced in 21-26 day old Diabetes Resis-
tant Bio-Breeding (DR-BB) Wistar rats using anti-RT6
monoclonal antibody (Dr. Dale Greiner, University of
Mass) DS4.23 hybridoma in 2 ml of tissue culture med-
ium injected 5 times/week in combination with polyino-
sinic-polycytidylic acid (Sigma), a non-specific immune
system activator at 5 μl/g of body weight 3 times/week.
Induction treatment was discontinued at the onset of
diabetes as determined by a blood glucose level above
250 mg/dL. Diabetes typically occurred 2-3 weeks after
the treatment was initiated. Within 1 week of diabetes
development, the diabetic rats were treated with insulin
(Humulin R, Humulin U and Humulin N; Eli Lilly,
Indianapolis, IN) through subcutaneous implantation of
an insulin-filled Alzet osmotic pump (Alza, model 2004,
0.25 μl/hr for 28 days; Mountain View, CA). Blood glu-
cose was closely monitored for the remaining time, and
hyperglycemic animals were given insulin injections as
needed in amounts based upon the severity of hypergly-
cemia. Control rats underwent the same manipulations
except pumps were filled with saline. Body weight and
blood glucose were followed weekly, with the final
values shown in Table 1. Diabetic animals (n = 7 female,
4 male) and their age matched controls (n = 6 female, 4
male) were euthanized after 8 weeks of diabetes.
Cell Dispersion
Dissected aortas and femoral arteries were cleaned of
adventitia in cold phosphate buffered saline (PBS) buf-
fer. The vessels were cut lengthwise to expose the
intima, which was gently swabbed to remove endothelial
cells. Each vessel was pinned, lumen side up, in a small
covered beaker containing Sylard Gel (Dow Corning,
Midland, MI) and bathed in collagenase solution con-
taining deoxyribonuclease I, collagenase type 2, soybean
trypsin inhibitor (Worthington Biochemical Corporation,
Lakewood, NJ) and bovine albumin (Sigma). After 30
minutes of shaking at 37°C, the first digest was dis-
carded as it contained predominantly endothelial cells.
New collagenase solution was added and further disper-
sions were gathered every 2 hours. Cells were gently
centrifuged to remove the enzyme solution before being
rinsed and re-suspended in media.
Cell Culture
Cells from the A7r5 cell line (American Type Tissue
Culture, Manassas, VA), derived from rat thoracic aorta,
were grown in Dulbecco’s Modified Eagle’s Medium
supplemented with 10% fetal bovine serum, penicillin,
and streptomycin at 37°C, 5% CO2. Cells were grown in
flasks, then seeded in 100 mm dishes or on coverslips
with glucose concentrations of either the supplier-
recommended concentration (25 mM; referred to as
medium) or high glucose (75 mM). Because 25 mM glu-
cose is high compared to physiological serum levels, a
third (low) glucose concentration was tested (5.5 mM).
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The effects of osmolarity were controlled by the addi-
tion of mannitol. Cells were grown to semi-confluence
prior to testing.
Immunoblotting
Total proteins were extracted from tissue or cell culture
using lysis buffer containing 10 mM Tris, pH 7.4, 1 mM
sodium ortho-vanadate and 1% SDS. To separate
nuclear and cytoplasmic proteins, the NE-PER kit
(Pierce, Rockford, IL) was used. Each sample was con-
centrated by ultrafiltration using Microcon YM-10
(Millipore, Bedford, MA). Protein concentrations were
measured in 96-well format using the BCA kit (Pierce,
Rockford, IL) and a MRX microplate reader (Dynex
Technologies, Chantilly, VA). A total of 30 or 50 μg of
protein was loaded in each lane of 8, 10 or 4-15% gels.
Rat cardiac tissue extract was used as a positive control
for ryanodine receptor (RyR) and A-10 cell lysate (Santa
Cruz, Santa Cruz, CA) was used for Inositol 1,4,5 tri-
sphosphate receptors (IP3Rs). After electrophoretic
separation, proteins were transferred from a gel to a
PVDF membrane (Pierce) overnight. Ponceau’s stain
(Sigma) was used to assess protein loading prior to blot-
ting. A standard immunoblotting protocol was per-
formed. Primary antibodies to SERCA2, SERCA3, IP3R
type I and RyR (Affinity BioReagents, Golden, CO), and
IP3R type 2 and IP3R type 3 (Santa Cruz) were used.
GAPDH was used as a housekeeping gene product (anti-
body, Santa Cruz). Anti-HSP90 (Santa Cruz) was used
to assess the purity of the cytoplasmic extractions and
anti-p62 (BD Transduction, Lexington, KY) or anti-USF-
2 (Santa Cruz) were used to test the purity of the
nuclear extracts. Detection was performed using
enhanced chemiluminescent reagent (Pierce) or Super-
Signal West Pico Chemiluminescent reagent (Pierce).
Duplicates were made of each immunoblot experiment.
Immunocytochemistry
A7r5 cells were grown on cover slips in various glucose
concentrations. Freshly dispersed VSMC were allowed to
attach to glass coverslips for at least 2-4 hours in PBS at
37°C prior to fixation with 2% paraformaldehyde (Fisher
Scientific, Palatine, IL). Fixed cells were rinsed with PBS,
permeabilized with 1% Triton X-100 (Sigma) and rinsed
well before blocking in 10% goat or donkey serum
(Jackson Immunoresearch Laboratories, West Grove, PA).
Cells were incubated with primary antibody (same as
above) diluted in 5% non-fat dry milk (Bio-Rad, Helcules,
CA) solution overnight in a cold box at manufacturer
recommended concentrations. Alpha smooth muscle actin
(Sigma) was used to identify SMC type. Cells were repeat-
edly rinsed in PBS before incubation with secondary anti-
body conjugated to Rhodamine Red or Cy 2 (Jackson
ImmunoResearch) in a dark chamber. Brefeldin A (Invi-
trogen, Carlsbad, CA) was used to evaluate sarcoplasmic
reticulum (SR). Coverslips were rinsed and allowed to air
dry in the dark before mounting. Images were captured
using an Olympus Fluoview 300 Confocal Microscope
with the consistent confocal settings for each pair of con-
trol and diabetic cells per single primary antibody. Experi-
ments were performed in triplicate.
Live Cell Intracellular Calcium Measurements
Freshly dispersed VSMCs or cultured A7r5 cells were
allowed to attach to coverslips for 1 hour in PBS at 37°
C before loading with 1 μM each of two Ca2+ sensitive
fluorophores, Fluo-4/AM and Fura-Red/AM (invitrogen)
by incubation at 37°C for 30-60 minutes. The coverslips
were inserted into an Attofluor chamber (Molecular
Probes) and rinsed with warm PBS. PBS with ethylene
glycol tetraacetic acid (EGTA) to buffer extracellular
Ca2+ (0 Ca2+), was added to the chamber mounted on
the stage of a confocal microscope so that the measured
Ca2+ changes were limited to the intracellular stores
only. Baseline measurements were taken on quiescent
cells for 3-4 minutes prior to the application of any ago-
nist. Vasopressin (10 nM, Sigma) or thapsigargin (20
μM, Sigma) were added to the bath at the times indi-
cated in the results section. Images were collected every
5 or 10 seconds using an inverted Nikon Eclipse TE
300/Bio-Rad MicroRadiance Plus Laser Scanning Confo-
cal Microscope (Bio-Rad Laboratories, Germany) or an
Olympus Fluoview 300 confocal microscope (Olympus,
Center Valley, PA). Fluoview software was used to ana-
lyze Ca2+ signaling experiments. Time-to-peak was
defined as the time of agonist application to the time
the maximal magnitude of the response was obtained.
The duration of the Ca2+ signal was defined as the time
from the upstroke of the response to the return within
25% of initial baseline value.
Table 1 Characteristics of Animal Models of Diabetes
Physiological Parameters
STZ-Induced Diabetic Rat Model DR-BB Diabetic Rat Model
Control Diabetic Control Diabetic
Weight (g) 453 ± 16 328 ± 14 * 217 ± 5 212 ± 19
Blood Glucose (mg/dL) 113 ± 5 554 ± 13 * 98 ± 2 295 ± 13 *
*Indicates a significantly different value when compared to respective controls (p < 0.001)
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Data analysis
All data points were normalized for background signal
prior to statistical analysis. Fluoview software (Olympus,
Melville, NY) was used to analyze Ca2+ signaling experi-
ments. Adobe Photoshop (Adobe Systems, San Jose,
CA) was used to analyze relative fluorescence intensity,
and color analysis. Analysis of variance was performed
for Ca2+ fluorescence and immunoblot density values
using Sigma Stat software. When appropriate, statistical
differences were assessed using Dunnett’s test for multi-
ple comparisons after a one-way analysis of variance
using Sigma Stat (SPSS Inc, Chicago, IL). A probability
level of p < 0.05 was defined as a significant difference.
Results
Animal Models of Diabetes
The blood glucose levels were significantly higher (p <
0.001) in both diabetic rat models. However, the animals
from the toxin-induced diabetes (STZ) were significantly
more hyperglycemic when compared to the genetically-
prone diabetic group (DR-BB) (Table 1, p < 0.001). This
difference is due to the fact that uncontrolled diabetes is
lethal in the DR-BB model and the animals were pro-
vided an insulin pump or injected with insulin daily
after each became diabetic. In contrast, the STZ animals
received no exogenous insulin. The body weight of con-
trol and diabetic DR-BB rats were comparable but in
the STZ diabetic rat model, the diabetic rats demon-
strated a significant decline in weight over time (Table
1, p < 0.001).
Diabetes Attenuated the Ca2+ responses in Freshly
Dispersed SMCs
Freshly dispersed VSMC from arteries of control and dia-
betic rats were evaluated for agonist-induced Ca2+ transi-
ents. Whole cell Ca2+ fluoremetry indicated that the
responses to vasoactive substances were significantly
blunted in the VSMC from diabetic animals. Mean Ca2+
responses to vasopressin and thapsigargin were both
blunted in VSMC from the aorta of DR-BB diabetic rats
(Figure 1A). In cells taken from femoral arteries, the
vasopressin response was blunted, but diabetes had no
effect on the peak of the thapsigargin response (Figure
1B). The peak of the vasopressin responses were delayed
only in the STZ diabetic animal model, and the thapsi-
gargin responses were delayed in both animal models
(Table 2). In addition, fewer VSMC from diabetic animals
responded to the vasopressin stimulation. VSMC from
control animals responded to vasopressin 78% of the
time, while only 45% of the VSMCs from diabetic rats
responded to vasopressin exposure. A decline in the
vasopressin amplitude of the responding cells was also
measured in VSMC from the STZ-induced diabetic ani-
mals when compared to the controls (results not shown).
To further define the changes in the Ca2+ signal, ratio-
metric fluorophores were utilized. With the ratiometric
dyes, it was clear that the nuclear and cytoplasmic com-
partments responded differently to agonist stimulation.
Resting Ca2+ concentrations in the nucleus were higher
than the cytoplasmic levels in control animals respective
to STZ or DR-BB diabetic rats (p < < 0.001). With dia-
betes, the resting Ca2+ concentration declined in both
the nucleus and the cytoplasm; however, the nuclear
decline was greater so that quiescent cells from diabetic
animals had similar nuclear and cytoplasmic Ca2+ con-
centrations (Figure 2A).
While whole-cell Ca2+ peaks declined by 30% with
diabetes (Figure 1), separate analysis of the cytoplasmic
and nuclear compartments demonstrated that most of
the difference was attributable to the nuclear compart-
ment. Figure 2B illustrates a significant decline in the
amplitude of the vasopressin-induced Ca2+ peak in the
nuclear compartment of both diabetic animal models
compared to their controls as determined by the change
of the fluorescence ratio (p < 0.01). The amplitude of
the nuclear thapsigargin response was not different in
VSMC from control or diabetic animals using either
animal model (Figure 2C).
In order to rule out general changes in the nuclear
envelope that could alter Ca2+ signaling, two nucleus-
specific proteins were analyzed. Both p62 and NUP153
are core components of the nuclear pore complex, and
levels and distribution of both proteins has been shown
to be associated with specific disease states [21]. Immu-
noblotting for p62 showed no difference in protein
levels in samples from control or diabetic animals. In
the STZ model of diabetes, the aortic VSMC p62 pro-
tein band density level was 67 ± 15 (arbitrary units) in
control animals, and 70 ± 16 in diabetic tissue (no sta-
tistical difference). Similar results were found in the DR-
BB aortic arteries. The values for p62 protein bands
were 114 ± 6 in controls and 92 ± 15 in diabetes. In the
femoral artery of the DR-BB animals, the levels were 62
± 10 for controls and 77 ± 6 in diabetic rats. Like p62,
levels of NUP153 also were not statistically different in
the STZ or DR-BB rats in either the aortic or femoral
VSMCs, suggesting that changes in nuclear Ca2+ transi-
ents were not likely associated with gross changes in
nuclear transport.
Hyperglycemia attenuates Ca2+ responses in cultured
VSMCs
To determine whether the blunted agonist responses
were due directly to the exposure to hyperglycemia or
were a physiological adaptation to long term diabetes,
cultured rat aortic VSMCs were grown in high glucose.
Figure 3A illustrates the increase in the resting intracel-
lular Ca2+ concentration that was 2-3 times higher in
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cells grown in high glucose, when compared to cells
grown in low or medium (the supplier’s suggested glu-
cose concentration). These findings are opposite of
those measured in cells from diabetic animals (either
model) and may explain some of the confusion in the
field regarding changes in resting cytoplasmic Ca2+ con-
centrations with diabetes. There was a significant differ-
ence between the high glucose condition and the other
two conditions (p < 0.0001). There was no statistically
significant difference in the free intracellular Ca2+
between the low glucose condition and the medium glu-
cose condition. In fact, there was no statistical difference
between the low and medium glucose conditions for all
assays tested. Therefore, only medium and high glucose
conditions are reported in this study.
When stimulated with vasopressin or thapsigargin,
cells responded with an immediate increase in intracel-
lular Ca2+ that was diminished by high glucose condi-
tions. Figure 3B illustrates the altered responses to both
vasopressin (time 0) and thapsigargin (TSG, arrow) from
cells grown in medium and high glucose conditions.
The different resting Ca2+ levels made it difficult to
determine a change in vasopressin- induced peak
responses. In order to compare the amplitude of the
responses, the differences in baseline Ca2+ concentra-
tions were normalized by dividing values by the resting
Ca2+ fluorescence values (F/Fo) following the methods
reported previously [22]. The normalization clearly illus-
trates the attenuated peak response of the cells to either
agonist in hyperglycemic conditions (Figure 3C).
As noted in the freshly dispersed VSMC cells from
diabetic rats, the hyperglycemic condition had the great-
est effect on the Ca2+ signal from within the nuclear
compartment. Using ratiometric Ca2+-sensitive fluoro-
phores, the amplitude of the Ca2+ signal to vasopressin
stimulation (at time 0) in the nuclear compartment was
shown to be decreased when A7r5 cells were grown in
high glucose (Figure 4A, p < 0.0001). However, high glu-
cose had no statistical effect on the Ca2+ transient in the
cytoplasm (Figure 4B). Likewise, the thapsigargin
response was blunted in the nucleus in cells grown in
high glucose (p < 0.001; Figures 4A and 4C) with little
effect on the cytoplasmic response.
Under medium and low glucose conditions, the timing
of the Ca2+ transient was synchronous between the
cytoplasmic and nuclear compartments of the A7r5
cells. Cells grown in medium and low glucose condi-
tions (n = 74 and 97 cells, respectively) displayed 99%
synchrony in the nuclear and cytoplasmic Ca2+ signals
Figure 1 Intracellular Ca2+ Transients were Altered by Diabetes. Whole cell vasopressin and thapsigargin-induced Ca2+ transients were
altered by diabetes in VSMC from the aorta and femoral artery. Vasopressin was applied to VSMCs from the aorta (A) or femoral artery (B) from
DR-BB rats at time 0. The time of the thapsigargin application is shown with the arrow (TSG). In both cases the vasopressin-induced Ca2+
transients were blunted in amplitude and thapsigargin responses were delayed in cells from diabetic rats. For all figures, blue shades indicate
data of cells from diabetic and control rats; green shades indicate data from cultured A7r5 cells grown in various glucose concentrations.
Table 2 Delay in Agonist-Induced Ca2+ Transient in SMC
from Diabetic Animals





Control Diabetic Control Diabetic
Vasopressin 17 ± 3 54 ± 14 * 22 ± 2 26 ± 3
Thapsigargin 35 ± 3 67 ± 9 * 41 ± 7 152 ± 23 *
*Indicates a significantly different value when compared to respective controls
(p < 0.05)
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Figure 2 Peak Ca2+ Transients were Blunted in Diabetes. A) Separate analysis of the nuclear and cytoplasmic compartments indicated that
most of the diabetes-induced changes in the Ca2+ transients occurred due to changes in the nuclear compartment. Ratiometric Ca2+-sensitive
fluorophores demonstrated the decline in the resting Ca2+ levels with diabetes that were especially dramatic in the nuclear compartment. The
figure illustrates results of cells from DR-BB rats. P < 0.05. * indicates a significant difference in the fluorescence levels between the nuclear and
cytoplasmic compartments in VSMC from control animals. ** indicates a significant decline in the resting Ca2+ concentration in cells from
diabetic animals compared to the control. There was no statistical difference noted in the nucleus and cytoplasm within cells from diabetic
aorta. B) The amplitude of the vasopressin-induced nuclear Ca2+ transients declined with diabetes in both diabetic animal models. * indicates a
significant difference between the control and diabetic groups, p < 0.05. C) There was no significant change in the amplitude of the
thapsigargin-induced nuclear Ca2+ transients in either diabetic animal model. * indicates p < 0.05. For Figure 2, n = 39 and 42 cells from control
and diabetic STZ rats, respectively. n = 24 and 22 cells from control and diabetic DR-BB rats, respectively.
Searls et al. Cardiovascular Diabetology 2010, 9:8
http://www.cardiab.com/content/9/1/8
Page 6 of 17
Figure 3 Peak Ca2+ Transients are Blunted in Response to Hyperglycemia in Culture. A) Basal intracellular Ca2+ concentrations increased in
VSMCs when grown in high glucose conditions as opposed to low or medium glucose (n = 30 cells/group). * Indicates p < 0.0001. B)
Stimulation of cells with vasopressin (time 0) and thapsigargin (TSG, arrow) illustrated blunted responses in cells grown in high glucose (n = 29
cells). C) The plot of the amplitude of the response to each agonist (normalized for the different basal Ca2+ levels) illustrates the differences in
the peak responses to vasopressin and thapsigargin (* indicates p < 0.05; n = 97 cells in low glucose and 138 in high glucose conditions).
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Figure 4 Nuclear Ca2+ Transients are Altered by High Glucose. A) Nuclear Ca2+ responses to vasopressin and thapsigargin (TSG) in A7r5 cells
grown in medium glucose or high glucose conditions are shown. Both the vasopressin (added at time 0) and the TSG (added at the arrow)
responses were blunted in the nuclei of cells grown in high glucose. (n = 15 cells/group, p < 0.0001) B) The mean peak amplitude of the Ca2+
response to vasopressin did not change significantly in the cytoplasm when cells were grown in high glucose. However, the nuclear
compartment showed significant reduction of the vasopressin response in high glucose (n = 94 cells) versus medium glucose (n = 37). (p <
0.001; indicated by *) C) The mean peak amplitude of the thapsigargin (TSG) response did not change significantly in the cytoplasmic
compartment with high glucose exposure, but was significantly blunted in the nuclear compartment (n = 37). (p < 0.001; indicated by *).
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produced by vasopressin or thapsigargin. Asynchrony
between the nuclear and cytoplasmic Ca2+ transients
with stimulation was significantly increased in cells
grown in high glucose, resulting in 13% of the total cells
demonstrating asynchronous behavior (n = 138 cells).
In addition to asynchronous behavior in response to
an agonist, 17% of the A7r5 cells exposed to high glu-
cose demonstrated large magnitude spontaneous nuclear
Ca2+ transients well above 100% of baseline fluorescence
levels in basal conditions (n = 42 cells; Figure 5). These
high magnitude spontaneous oscillations appeared after
10 hours of incubation in high glucose media, but not
before. In these cells, the cytoplasm demonstrated either
a delayed oscillation or no oscillation at all (not shown).
No spontaneous nuclear Ca2+ oscillations were noted in
the cells grown in medium (n = 61cells) or low (n = 34
cells) glucose.
Diabetes and Hyperglycemia Altered Levels of SERCA
Proteins
In order to explain the dramatic changes in Ca2+ signals
caused by diabetes and hyperglycemia, intracellular Ca2+
regulatory proteins including Ca2+ pumps and channels
were measured for protein levels and localization. Rest-
ing intracellular Ca2+ levels in VSMCs are maintained
by plasma membrane and intracellular Ca2+ pumps
(SERCA). The amount of the SR Ca2+ pump (SERCA2
and SERCA3) protein in aortic VSMCs was significantly
lower with diabetes in both animal models tested. Figure
6A illustrates a typical immunoblot from the aorta of
DR-BB diabetic rats and their matched controls. Each
lane represents the protein extract from a single animal.
Levels of GADPH were not altered by diabetes in either
animal model. Thus, GADPH was used to normalize the
protein band density values, provided in Table 3. To
illustrate the changes, the percent decline in the mean
protein band density normalized per GAPDH content,
in the aorta from diabetic DR-BB and STZ animals was
compared to nondiabetic controls and plotted in Figure
6B. The figure shows that in the genetically-prone DR-
BB animals there was a 48% decline in SERCA2 levels
and a 52% decline in SERCA3 when compared to the
aorta of matched non-diabetic rats. These declines were
consistent when VSMCs from the femoral arteries were
tested (Table 3). There was a 32% decline in the amount
of SERCA2 from the femoral artery of STZ diabetic rats
compared to the non-diabetic controls. Only SERCA3
levels in the STZ-induced diabetic rat aortas failed to
demonstrate a significant difference when comparing
the values from the diabetic to non-diabetic control
animals.
Figure 7 depicts the protein levels and compartment
localization of different isoforms of Ca2+ channels and
pumps when A7r5 cells were grown in medium or high
Figure 5 High Amplitude Spontaneous Nuclear Ca2+ Oscillations Occur in High Glucose. In high glucose, A7r5 cells (n = 42) often
demonstrated large spontaneous nuclear Ca2+ transients. Spontaneous nuclear Ca2+ activity in three individual cells, resting in high glucose
conditions, depicts high amplitude oscillations in two cells represented by black and red lines (1 and 3 oscillations, respectively). In the same
field, some of the cells failed to elicit any spontaneous oscillations as indicated with the green line.
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glucose conditions. In immunoblotting experiments, the
amount of SERCA2 protein in the cytoplasmic fraction
remained unchanged with high glucose, but SERCA2
levels increased in the nuclear extract with high glucose
treatment, although it is important to note that the
nuclear SERCA2 levels were still low with high glucose
exposure. In low and medium glucose conditions, there
was no detectible SERCA2 in the nuclear fraction, but
in high glucose a clear band appeared. In contrast,
SERCA3 was detected primarily in the nuclear extracts
with cytoplasmic bands faintly visible. There was an
average of a 60% decrease in the amount of SERCA3 in
the nucleus with high glucose treatment. The majority
of HSP-90 was found in the cytoplasm while USF-2 was
strictly nuclear, validating the purity of the nuclear and
cytoplasmic extracts (not shown).
Diabetes and Hyperglycemia Alter Distribution of SERCA
Proteins
While immunoblots using fractionated samples gave
clues as to the distribution of the Ca2+ regulating pro-
teins, immunofluorescence provided more detailed
information. SERCA2 immunostaining illustrated the
intricate web of SR with a more pronounced perinuclear
staining in cells from the DR-BB rats (Figure 8A). Dia-
betes induced a further shift in fluorescence to the
Figure 6 Ca2+ Regulatory Protein Levels Change with Diabetes. A) Representative immunoblots for the SERCA proteins from control and
diabetic DR-BB rat aorta. Each lane was loaded with protein from an individual animal. B) Plot illustrates the decline in aortic protein levels of
the SR Ca2+ ATPases (SERCA2 and SERCA3) and the IP3 receptors (type 1 and 2). Diabetes corresponded with a reduction in protein levels for all
Ca2+ regulatory proteins in both the STZ and DR-BB animal models, with one exception. The level of SERCA3 did not decline significantly with
diabetes in the STZ model. * indicates a significant decline from non-diabetic rats, p < 0.05
Table 3 Levels of Ca2+ Regulatory Proteins are Changed with Diabetes











SERCA 2 165 ± 4 121 ± 12 * 120 ± 15 81 ± 9 * 108 ± 3 56 ± 2 *
SERCA 3 69 ± 19 60 ± 14 161 ± 13 110 ± 15 * 78 ± 5 38 ± 15 *
IP3 R type 1 40 ± 9 19 ± 8 * 213 ± 22 228 ± 28 135 ± 23 42 ± 6 *
IP3 R type 2 ND ND ND ND 37 ± 4 18 ± 3 *
RyR 38 ± 5 95 ± 8 * ND ND 11 ± 5 72 ± 59
*Indicates a significantly different value when compared to respective controls (p < 0.05)
ND = not done
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nucleus in DR-BB rats with a decline in total cellular
fluorescence intensity (Figure 8B). Interestingly, 6% of
the cells from controls and 21% from diabetic DR-BB
animals were positive for nuclear staining for SERCA2.
The decline in total SERCA2 in the cells from diabetic
animals was noted in both rat models (Figure 8A-D). In
the A7r5 cultured VSMCs, SERCA2 had a more wide-
spread distribution in cells grown in medium glucose
(Figure 8E). Identical to the changes noted in the cells
from the diabetic animals, there was a distinct localiza-
tion to the nuclear SR with a decline in peripheral SR
staining with high glucose treatment (Figure 8F). This
finding is also consistent with the immunoblot results
shown in Figure 7.
SERCA3 immunostaining patterns were generally the
same in cells from both animal models exhibiting cyto-
plasmic staining with partial nuclear exclusion (Figure
8G-L). However, in 17% of the cells from either control
or diabetic DR-BB rats, nuclear staining was noted (Fig-
ure 8H). Overall, diabetes had no significant effect on
the location of the SERCA3 protein in aortic VSMCs. In
cultured A7r5 cells, SERCA3 had strong nuclear staining
with little cytoplasm staining, which was not altered in
the high extracellular glucose condition (Figure 8K and
8L). In order to determine whether the distribution of
the SR changed with high glucose, cells were double
labeled with SERCA 2 and an SR stain, Brefeldin A. Bre-
feldin A levels were not affected by diabetes (Figure 9)
or hyperglycemia when analyzed for cellular fluores-
cence values or for subcellular distribution (not shown).
Diabetes and Hyperglycemia Altered Levels of
Intracellular Ca2+ Channels
The channels responsible for releasing Ca2+ from the
intracellular stores are the inositol trisphosphate recep-
tor (IP3R) and the ryanodine receptor (RyR). There are
three subtypes of IP3Rs, and each was examined in the
aorta of the diabetic animal models and in cultured cells
exposed to hyperglycemic conditions. Type 1 IP3Rs
(IP3R-1) showed a significant decline in levels in the
aortas from both models of diabetes with a 69% decline
in the DR-BB diabetic animals and a 53% decline in the
STZ rats (Figure 6B, Table 3). Type 2 IP3R (IP3R-2)
were only tested in the genetically-prone DR-BB model
Figure 7 Ca2+ Regulatory Protein Levels Altered in Cultured VSMC Grown in High Glucose. Immunoblots of the SERCA and IP3R isoforms
in cytoplasmic and nuclear extracts from A7r5 cells grown in high or medium glucose concentrations are shown. SERCA2 protein levels
remained steady in the cytoplasm, but an increase was observed in the nuclear extract from cells in high glucose. SERCA3 in the cytoplasm was
detected at equally low levels in either glucose concentration. Nuclear SERCA3 levels were reduced with hyperglycemic treatment. All IP3Rs
showed a reduction in protein levels in response to high glucose.
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of diabetes, showing a significant decline with diabetes.
IP3R type 3 (IP3R-3) levels were not detected in
amounts allowing immunoblot analysis of protein levels
in either animal model.
A reduction in the levels of the IP3R prompted inves-
tigation of the other major SR Ca2+ release channel in
smooth muscle cells, the RyR to determine whether its
subcellular distribution changed, possibly in response to
changes in the IP3R. We hypothesized that the RyR
could be either down-regulated due to a decline in cel-
lular Ca2+ signaling or upregulated as a compensatory
mechanism for the decline in IP3R protein levels and
cellular signaling. The RyR, increased dramatically with
diabetes, regardless of the animal model (Table 3). In
the STZ rats there was 2.5 times more RyR measured in
the aorta when compared to non-diabetic controls.
Interestingly, in the DR-BB rats there was an exquisite
correlation between glucose levels and the amount of
RyR. If the blood glucose was greater than 300 mg/dL
on the day of sacrifice, then higher RyR levels were
noted. However, if the diabetic rat had a lower glucose
reading on that day, even if they had been hyperglyce-
mic in the past, the changes in the RyR levels were
minimal. This variability resulted in a lack of statistically
significant differences found when comparing the dia-
betic to the control animals (Table 3).
Figure 8 SERCA2 and SERCA3 Shift to a More Nuclear and Perinuclear Distribution in Conditions of Diabetes and Hyperglycemia.
Immunofluorescence shows the distribution of proteins in cells from control and diabetic rats from both the DR-BB (A, B, G, and H) and STZ
diabetic model (C, D, I, and J), and in A7r5 cells cultured with medium (E and K) or high glucose concentrations (F and L). Examples show a
more localized perinuclear and nuclear distribution of SERCA2 in both animal models when diabetes was developed. In addition there was a
decrease in the total fluorescence for SERCA3 in both animal models. Hyperglycemia also induced a redistribution of SERCA2 and SERCA3 to the
nucleus.
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In cultured VSMCs exposed to hyperglycemia, a
decreased amount of protein for all three IP3R subtypes
was observed under high glucose conditions (Figure 7).
The levels of IP3R-1 decreased nearly 2.5 fold with high
glucose exposure (Table 3). Although there was variabil-
ity in the amount of protein normally present between
the cytoplasm and nuclear compartments, in all cases
high glucose treatment reduced the amount of IP3R-1 in
each compartment. IP3R-2, detected mainly in nuclear
extracts decreased 20% with high glucose exposure (Fig-
ure 7). IP3R-3 was detected in both the nucleus and
cytoplasm in medium glucose conditions. However, in
high glucose the levels decreased an average of 90% in
the cytoplasm and decreased 30% in the nucleus (Figure
7).
Diabetes and Hyperglycemia Altered the Distribution of
Intracellular Ca2+ Channels
The IP3R-1 immunostaining displayed a generally even
cellular distribution in cells from control and diabetic
rats with a significant overall decline (p < 0.002) in cel-
lular fluorescence intensity in the VSMCs from diabetic
aortas (not shown) and from cultured A7r5 cells (Figure
10A and 10B). IP3R-2 labeling was less intense in the
cells from both models of the diabetic rats compared to
non-diabetic controls, but there was no change in the
pattern of immunostaining for the IP3R-2. In contrast,
IP3R-2 was localized strictly to the nuclear regions in
both experimental conditions in A7r5 cells (Figure 10C
and 10D). While IP3R-3 could not be detected suffi-
ciently by immunoblot analysis, it could be evaluated by
immunofluorescence. Like the other subtypes, IP3R-3
demonstrated a significant decrease in the total fluores-
cence with diabetes (in both animal models) and when
cultured in hyperglycemia (p < 0.02; Figure 10E and
10F).
RyR immunostaining was primarily cytoplasmic with
nuclear exclusion as the most common pattern,
although some cells showed a more generalized staining
in control that included the nuclear region. While the
distribution of RyR was similar to the IP3R pattern, the
fluorescence intensity was affected by diabetes in a man-
ner that was just opposite to the IP3R response. Consis-
tent with the protein levels measured with
immunoblotting, the VSMCs from diabetic rats demon-
strated significantly higher levels of RyR immunostaining
compared to the cells from control animals (not shown).
This was true of both diabetic animal models and A7r5
cells grown in high glucose concentrations. Immunos-
taining of the RyR demonstrated primarily patchy cyto-
plasmic staining with strong perinuclear localization
(Figure 10G). A predominant relocation to the nucleus
was observed for the RyR when cells were grown in
high glucose (Figure 10H).
Discussion
VSMC dysfunction and subsequent disease is the main
cause of mortality in type 1 diabetes, but the underlying
mechanisms are largely unknown. In normal (medium)
glucose conditions reported here, the distribution of the
IP3R subtypes, RyR, and SERCA were similar to other
studies using primary aortic SMCs [23], rabbit aortic
SMCs [24], and cultured cell lines [25]. Studies involving
rat heart [26], islet cells and kidney [27] using diabetic
animal models have demonstrated alterations in IP3R-1,
SERCA2 and SERCA3 expression in a manner very con-
sistent with our results from VSMCs.
The results of this study clearly demonstrate changes
in the regulatory proteins associated with intracellular
Ca2+ storage and release in aortic and femoral VSMCs.
These changes lead to altered Ca2+ signaling in the cyto-
plasmic and nuclear compartments in response vaso-
pressin. VSMCs from two different diabetic rat models
showed a decline in the levels of IP3R and SERCA pro-
tein with diabetes. Changes in the distribution of the
IP3R subtypes and SERCA subtypes were dependent on
the rat model, but fully supported the immunoblot
results of overall decreased amounts. To measure the
relative role of hyperglycemia on the above mentioned
changes, rat aortic cultured cells (A7r5) were exposed to
various concentrations of glucose. Like the freshly dis-
persed cells from the diabetic animals, cultured cells
exposed to high glucose had blunted Ca2+ responses to
vasopressin and decreased levels of Ca2+ regulatory pro-
teins. Thus, the changes noted in vSMCs from diabetic
animals were likely due to exposure of the vSMCs to
hyperglycemic conditions rather than adaptation of the
cells to the complex disease of diabetes. This is the first
Figure 9 Marker for SR Protein Levels Are Not Altered with
Diabetes. Fluorescence values from cells stained for SR area, using
Brefeldin A as a marker, showed no differences between cells from
control of diabetic animals, regardless of the type of diabetic animal
model.
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study to report of both diminished levels and subcellular
redistribution of key Ca2+ regulatory proteins in cul-
tured and freshly dispersed VSMCs.
Previous studies have described a blunted Ca2+
response in VSMCs from diabetic animals [28-30].
Unique to this study was the identification of separate
nuclear and cytoplasmic responses, and the presence of
spontaneous nuclear Ca2+ oscillations. Such oscillations
in A7r5 cells have been reported to be associated with
intracellular Ca2+ stores and entry of Ca2+ from the
extracellular milieu [31,22]. Others have shown sponta-
neous Ca2+ sparks occurring around the nucleus of pri-
mary VSMCs [32]. The effect of glucose on the
spontaneous nuclear oscillations has not been previously
published. In this study, the high magnitude sponta-
neous oscillations in resting cells bathed in high glucose
were intracellular Ca2+ release events as all experiments
were performed in zero extracellular Ca2+.
In order to thoroughly examine the effects of hyper-
glycemia on VSMC function, two different animal mod-
els of type 1 diabetes were utilized; the toxin-induced
STZ diabetic rat and the immune/inflammation model
of type 1 diabetes, the DR-BB rat. The differences noted
between the two models were minor, but in general the
diabetes induced changes were more robust in the DR-
BB rats. It is possible that any small differences we
noted between rat models were a function of the rat
strain, the method of diabetic induction, or the adminis-
tration of insulin to the DR-BB animals.
In VSMCs, much of the ability to remove Ca2+ from
the cytoplasm is dependent on the SERCA proteins on
the SR and nuclear envelope, estimated to be responsi-
ble for over 40% of the Ca2+ buffering in VSMCs
[33,34]. Importantly, by maintaining low intracellular
Ca2+, SERCA inhibits migration of VSMCs into the
intima of the vessel [35], a common hallmark of dia-
betes-induced vascular disease. In general, SERCA2
and SERCA3 protein levels were decreased and their
distribution altered in the diabetic rats. Brefeldin A
staining of the SR did not show a corresponding loss
or reorganization of the SR with hyperglycemia, sug-
gesting that these were pump-specific changes. In con-
trast to a previous report [36], we did not measure an
increase in degradation in SERCA proteins with dia-
betes. In VSMCs from diabetic animals, SERCA2
shifted from a generalized SR distribution to a perinuc-
lear location coupled with an overall decrease in the
SERCA protein levels. SERCA2 is the primary Ca2
+-ATPase of the SR in VSMCs and is thought to be
most important in cytoplasmic Ca2+ buffering [37].
Changes in the thapsigargin-induced Ca2+ transient
suggest that the decrease in protein levels affected the
ability of the cells to buffer Ca2+ via SERCA as has
been shown in other labs [38].
The function of SERCA3 in VSMCs still remains elu-
sive. Originally SERCA3 was reported to be absent from
muscle cells. However, thorough examination of tissues
with subtype-specific antibodies, revealed that at least
one member of the SERCA3 family was equally
expressed in all tissues tested [39]. In human vascular
endothelial cells, chronic stimulation with histamine
caused an upregulation in the SERCA3 protein, which
allowed quicker sequestration of Ca2+ from the cyto-
plasm following stimulation [40]. Given such results in
endothelial cells, it is reasonable to consider that a
decrease in the SERCA3 levels could partially explain
the delayed and blunted response to thapsigargin in the
VSMC shown here. The importance of this little defined
protein should not be overlooked, as the SERCA3 locus
has been implicated in the genetic susceptibility in
human type 2 diabetes [41].
Vascular reactivity to vasopressin in diabetes varies
between vascular beds [42,43]. For this reason, the pro-
tein levels and Ca2+ responses were tested in VSMCs
from both the aorta and the femoral arteries. The dia-
betes-induced changes in protein levels and in the Ca2+
responses were the same in VSMCs from either location
with the exception of SERCA2 levels, which were
increased in the femoral artery, but decreased in the
aortic VSMCs in the STZ rat. This increase in the
femoral artery agrees with a study finding increased
SERCA activity and levels in resistance arteries from
diabetic dyslipidemic pigs [44]. SERCA2 may be of more
functional importance in the resistance arteries so these
findings may serve as a cautionary note for researchers
drawing conclusions from aortic tissue alone.
When analyzing the Ca2+ channel activity, the results
presented here build on earlier work by Ma et al., illus-
trating a decline in IP3 responses in VSMCs from STZ
treated rats [28]. The Ma paper showed a decline in ves-
sel contractility and in intracellular Ca2+ responses via
IP3 receptors and Ca
2+ influx across the plasma mem-
brane. A decrease in IP3R-1 levels in diabetic arteriolar
SMCs has been published previously [45]. The current
study focused the question on the level of specific Ca2+
regulatory proteins on the SR by conducting live cell
experiments in zero extracellular Ca2+ conditions.
Further, we showed that the findings were not depen-
dent on the mode used to induce diabetes, using either
a toxin-induced rat model or genetically-bred animals,
as the results were generally consistent in the aorta and
femoral arteries of the STZ and DR-BB animals. The
results suggest that the decreased activity in the VSMCs
associated with diabetes is due to shared changes in the
SR Ca2+ release channels (IP3R) and SERCA resulting in
diminished Ca2+ transients, especially in the nuclear
compartment. In addition to selectively activating genes,
nuclear Ca2+ may also play an important role in
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Figure 10 IP3R and RyR Protein Distribution Changes with High Glucose Treatment. Immunofluorescence experiments picture the relative
location of each IP3R isoform in the cells grown in medium and high glucose. Few changes were noted in the distribution of IP3R-1 (A and B).
There was a loss in fluorescence in IP3R-2 (C and D) and IP3R-3 (E and F) with high glucose treatment are shown. Cells grown in medium
glucose conditions displayed primarily cytoplasmic staining of the RyR with perinuclear localization (G). RyR in cells grown in high glucose
exhibited strong nuclear localization (H).
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stabilizing mRNA in a variety of cell types [46]. The
functional impact on differential gene expression of
decreased Ca2+ responses in VSMCs as a result of dia-
betes is a question that should be intensely pursued,
given the findings of this study.
The similarity of the results from identical experi-
ments conducted in freshly dispersed cells from diabetic
and control rats, and cultured rat aortic cells grown in
normal and high glucose are striking and underlie the
importance of chronic exposure to glucose as a major
inducer of changes in intracellular Ca2+ regulation. Pre-
vious studies have shown direct effects of glucose on
cultured cells, but have typically worked with primary
cultures [47,48,35]. In such cases 20-25 mM Ca2+ in the
extracellular media was sufficient to elicit a response
similar to that seen in cells from diabetic animals. Due
to the fact that we utilized a cultured cell line in which
the normal growth media contained 25 mM glucose
(referred to as medium in this study), we had to increase
the glucose concentration dramatically to evoke a dia-
betes-like response. While the sensitivity to glucose was
different in the culture cells, the other characteristics of
the glucose-induced change in freshly dispersed and cul-
tured cells were exceedingly similar.
The importance of separating the nuclear Ca2+
response from cytoplasmic may not be immediately
clear. We are not the first to report on selective Ca2+
signals in the nuclear that were unique from the cyto-
plasm as Bkaily et al demonstrated in neurons [49,50].
Nuclear and cytosolic Ca2+ have been reported to be
regulated independently in several cell types [51,52].
Zones of Ca2+ signaling around and within the nucleus
of smooth muscle cells have led some to suggest that
clusters of lysosomes with high densities of RyR form in
the perinuclear region forming physical junctions with
the SR to comprise a trigger zone of Ca2+ [53]. The
result of the depressed nuclear Ca2+ signal with high
glucose is unknown, but it is likely that VSMCs have
nuclear-specific Ca2+ transcription regulated pathways
just as neurons have been shown to possess [54,55].
Conclusion
While diabetes is a complex disease that includes hyper-
glycemia, hypoinsulinemia or hyperinsulinemia and
numerous adaptations in metabolic proteins as well as
changes in regulatory factors, it appears that high glu-
cose is predominantly responsible for the decreased IP3-
induced Ca2+ transients noted previously in VSMCs
from diabetic animals. This is likely due to the altered
distribution and/or levels of Ca2+ regulatory proteins
including the IP3R, RyR, and SERCA. Determining how
diabetes changes protein distribution and amounts is
paramount, as these changes clearly have downstream
effects within the cells that may be linked to cell prolif-
eration and migration.
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